Drug Profile

Iron sucrose - Renibus Therapeutics

Alternative Names: FeS - Renibus Therapeutics; RBT-3

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Renibus Therapeutics
Class Antianaemics; Carbohydrates; Ferric compounds; Small molecules
Mechanism of Action Iron replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Chemotherapy-induced damage; Iron deficiency anaemia

Most Recent Events

28 Jul 2024 No recent reports of development identified for preclinical development in Iron deficiency anaemia in USA
28 Mar 2024 No recent reports of development identified for phase-I development in Chemotherapy-induced-damage(Prevention) in USA
05 Jan 2023 Renibus Therapeutics plans to enter clinical development by 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com